

AMENDMENTIn the claims

1. (Twice Amended) A compound having structural homology to a contiguous sequence of amino acids within the sequence representing residues 149-1[7]97 of the G protein of respiratory syncytial virus, in which
- a) no oligosaccharide is linked to potential serine, threonine or asparagine attachment sites;
- b) four cysteine residues are involved in disulphide linkages; and
- c) the pattern of disulphide linkage is Cys 173 linked to Cys 186, and Cys 176 linked to Cys 182,
- and in which said compound possesses a biological activity of respiratory syncytial virus G protein.

7. (Twice Amended) A compound according to Claim 6, selected from the group consisting of:

acetyl-KQRQNKPPSKPNNDFHFEVFNFVPCSI CSNNPTCWAICKRIPNKKPGKKAmide

acetyl-KQRQNKPPSKPNNDFHFEVFNFVPC[G]SICGAmide,

in which the cysteine residues are derivatized with acetamidomethyl

fluoresceinisothiocarbamyl β -

alanylKQRQNKPPSKPNNDFHFEVFNFVPCSI CSNNPTCWAICKRIPNKKPGKKAmide

fluoresceinisothiocarbamyl β -alanylHFEVFNFVPCSI CSNNPTCWAIC

KRIPNKKPGKKAmide

benzoylbenzyl-KQRQNKPPSKPNNDHFHFEVFNFPVCSICSNNPTCWAICKRIPNKKPGKK

Amide

biotinyl-KQRQNKPPSKPNNDHFHFEVFNFPVCSICSNNPTCWAICKRIPNKKPGKKAmide

acetyl-FHFEVFNFPVCSICSNNPTCWAICKRIPNKKPGKKAmide[,

in which the cysteine residues are derivatised with acetamidomethyl].

14. (Twice Amended) A diagnostic composition comprising a compound selected from the group consisting of the compounds of claims 1 to [10]7, the compounds of claims 1 to 6 that are peptidomimetic compounds, the compounds of claims 1 to 7 in which one or more amino acids is replaced by its corresponding D-amino acid, and the compounds of claims 1 to 7 in which one or more individual amino acids is replaced by an analogous structure, together with an acceptable carrier.

15. (Twice Amended) A pharmaceutical composition comprising a compound selected from the group consisting of the compounds of claims 1 to [10]7, the compounds of claims 1 to 6 that are peptidomimetic compounds, the compounds of claims 1 to 7 in which one or more amino acids is replaced by its corresponding D-amino acid, and the compounds of claims 1 to 7 in which one or more individual amino acids is replaced by an analogous structure, together with a pharmaceutically acceptable carrier.

19. (Twice Amended) A composition according to [any one of] Claim 14 in which the virus is human RSV.

20. (Twice Amended) A composition according to [any one of] Claim 15 in which the virus is human RSV.

22. (Twice Amended) A method of prevention or treatment of *Pneumovirus* infection comprising the step of administering an effective amount of a compound selected from the group consisting of the compounds of claims 1 to [10]7, the compounds of claims 1 to 6 that are peptidomimetic compounds, the compounds of claims 1 to 7 in which one or more amino acids is replaced by its corresponding D-amino acid, and the compounds of claims 1 to 7 in which one or more individual amino acids is replaced by an analogous structure, to a mammal in need of such treatment.

24. (Twice Amended) A method of immunisation against *Pneumovirus* infection, comprising the step of immunising a mammal at risk of such infection with an immunising-effective dose of a compound selected from the group consisting of the compounds of claims 1 to [10]7, the compounds of claims 1 to 6 that are peptidomimetic compounds, the compounds of claims 1 to 7 in which one or more amino acids is replaced by its corresponding D-amino acid, and the compounds of claims 1 to 7 in which one or more individual amino acids is replaced by an analogous structure, said compound being immunogenic and having the ability to elicit protective antibody.